Allogene Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q4 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Allogene Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2017 to Q4 2024.
  • Allogene Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$60.5M, a 28.9% increase year-over-year.
  • Allogene Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$273M, a 16.6% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$273M, a 16.6% increase from 2023.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$328M, a 2.32% increase from 2022.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$336M, a 86.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 -$60.5M +$24.6M +28.9% Dec 31, 2024 10-K 2025-03-13
Q3 2024 -$71.8M -$8.78M -13.9% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$71.4M +$9.11M +11.3% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$69.5M +$29.6M +29.9% Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$85.1M +$11.3M +11.7% Dec 31, 2023 10-K 2025-03-13
Q3 2023 -$63M +$19.5M +23.7% Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$80.5M -$3.92M -5.12% Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$99.1M -$19.1M -23.8% Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$96.4M -$98.1M -5744% Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$82.5M -$4.84M -6.23% Sep 30, 2022 10-K 2024-03-14
Q2 2022 -$76.6M -$5.59M -7.87% Jun 30, 2022 10-K 2024-03-14
Q1 2022 -$80M -$46.8M -141% Mar 31, 2022 10-K 2024-03-14
Q4 2021 $1.71M +$71.1M Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$77.7M -$9.63M -14.2% Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$71M -$7.87M -12.5% Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$33.2M +$24.5M +42.4% Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$69.4M -$4.79M -7.41% Dec 31, 2020 10-K/A 2024-03-14
Q3 2020 -$68M -$13M -23.7% Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$63.2M -$17.2M -37.4% Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$57.7M -$21.2M -58.2% Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$64.6M -$31.5M -95.4% Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$55M -$32.8M -148% Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$46M +$89.1M +66% Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$36.5M -$33.9M -1304% Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$33M -$33M Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$22.2M Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$135M Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$2.6M Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$2K* Dec 31, 2017 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.